Free Trial

Denali Therapeutics (DNLI) Competitors

Denali Therapeutics logo
$16.26 -0.70 (-4.10%)
As of 12:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DNLI vs. BEAM, ABVX, RNA, CYTK, MRUS, RYTM, CRSP, GRFS, NUVL, and AXSM

Should you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Beam Therapeutics (BEAM), Abivax (ABVX), Avidity Biosciences (RNA), Cytokinetics (CYTK), Merus (MRUS), Rhythm Pharmaceuticals (RYTM), CRISPR Therapeutics (CRSP), Grifols (GRFS), Nuvalent (NUVL), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

Denali Therapeutics vs. Its Competitors

Denali Therapeutics (NASDAQ:DNLI) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Denali Therapeutics currently has a consensus target price of $33.50, indicating a potential upside of 105.96%. Beam Therapeutics has a consensus target price of $45.92, indicating a potential upside of 69.36%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Denali Therapeutics is more favorable than Beam Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Denali Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
3 Strong Buy rating(s)
3.06
Beam Therapeutics
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
3 Strong Buy rating(s)
2.94

Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -661.31%. Denali Therapeutics' return on equity of -40.79% beat Beam Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Denali TherapeuticsN/A -40.79% -36.39%
Beam Therapeutics -661.31%-43.15%-31.06%

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Denali Therapeutics had 7 more articles in the media than Beam Therapeutics. MarketBeat recorded 13 mentions for Denali Therapeutics and 6 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.72 beat Denali Therapeutics' score of 0.52 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Denali Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Beam Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Denali Therapeutics has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500.

Beam Therapeutics has higher revenue and earnings than Denali Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Denali TherapeuticsN/AN/A-$422.77M-$2.80-5.81
Beam Therapeutics$60.27M45.51-$376.74M-$4.50-6.02

Summary

Denali Therapeutics beats Beam Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Denali Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DNLI vs. The Competition

MetricDenali TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.40B$3.44B$6.24B$10.56B
Dividend YieldN/A2.27%5.74%4.88%
P/E Ratio-5.8522.9129.0627.16
Price / SalesN/A443.52554.75166.44
Price / CashN/A46.9837.4561.65
Price / Book1.9110.4512.326.45
Net Income-$422.77M-$52.55M$3.32B$276.51M
7 Day Performance-0.28%-1.35%-1.25%-2.38%
1 Month Performance22.11%9.71%5.22%0.49%
1 Year Performance-38.13%11.40%61.35%30.73%

Denali Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DNLI
Denali Therapeutics
4.2188 of 5 stars
$16.27
-4.1%
$33.50
+106.0%
-35.7%$2.40BN/A-5.85430
BEAM
Beam Therapeutics
3.6144 of 5 stars
$25.39
-3.5%
$45.92
+80.8%
+29.1%$2.66B$63.52M0.00510News Coverage
ABVX
Abivax
3.425 of 5 stars
$95.63
+2.0%
$114.25
+19.5%
+773.0%$7.30BN/A0.0061Short Interest ↓
RNA
Avidity Biosciences
2.6305 of 5 stars
$48.96
-1.6%
$68.32
+39.5%
+5.0%$7.26B$10.90M-13.75190
CYTK
Cytokinetics
3.8753 of 5 stars
$59.59
-0.7%
$76.64
+28.6%
+7.4%$7.18B$18.47M-11.68250Analyst Forecast
Insider Trade
MRUS
Merus
1.4785 of 5 stars
$94.85
+0.5%
$93.12
-1.8%
+83.3%$7.14B$36.13M-17.2537Short Interest ↓
RYTM
Rhythm Pharmaceuticals
3.0346 of 5 stars
$100.77
0.0%
$106.64
+5.8%
+113.5%$6.70B$130.13M-33.48140Insider Trade
CRSP
CRISPR Therapeutics
2.1444 of 5 stars
$68.29
-6.5%
$71.71
+5.0%
+49.1%$6.65B$37.31M-12.58460Insider Trade
GRFS
Grifols
3.957 of 5 stars
$9.45
+1.4%
$10.30
+9.0%
+9.0%$6.41B$7.81B8.0823,822Positive News
NUVL
Nuvalent
2.7294 of 5 stars
$89.75
+1.9%
$118.89
+32.5%
-3.9%$6.35BN/A-18.3240Analyst Revision
AXSM
Axsome Therapeutics
4.7456 of 5 stars
$121.15
-0.5%
$177.93
+46.9%
+43.6%$6.07B$385.69M-23.90380Positive News
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:DNLI) was last updated on 10/22/2025 by MarketBeat.com Staff
From Our Partners